Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 22051 AL 22065

Reliability and validity of the Norwegian version of the Brief Agitation Rating Scale (BARS) in dementia

Sommer OH, Engedal K.

Aging Ment Health. 2011 Mar;15(2):252-8. doi: 10.1080/13607863.2010.519318. Epub 2010 Dec 6.

Factors of error and effort in memory intervention for patients with Alzheimer's disease and amnesic syndrome

Mimura M, Komatsu S.

Psychogeriatrics. 2010 Dec;10(4):179-86. doi: 10.1111/j.1479-8301.2010.00339.x.

[Effects of amyloid β-protein on hippocampal long-term potentiation]

Zhang JF, Yang D, Qi JS.

Sheng Li Xue Bao. 2010 Dec 25;62(6):479-88.

Interleukin-6 gene (-174 C/G ) and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population

Klimkowicz-Mrowiec A, Wołkow P, Spisak K, Maruszak A, Styczyńska M, Barcikowska M, Szczudlik A, Słowik A.

Neurol Neurochir Pol. 2010 Nov-Dec;44(6):537-41. doi: 10.1016/s0028-3843(14)60149-3.

Working memory, attention, and executive function in Alzheimer's disease and frontotemporal dementia

Stopford CL, Thompson JC, Neary D, Richardson AM, Snowden JS.

Cortex. 2012 Apr;48(4):429-46. doi: 10.1016/j.cortex.2010.12.002. Epub 2010 Dec 21.

Preventing Alzheimer's disease and cognitive decline

Williams JW, Plassman BL, Burke J, Benjamin S.

Evid Rep Technol Assess (Full Rep). 2010 Apr;(193):1-727.

A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease

Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K.

Int J Geriatr Psychiatry. 2011 Sep;26(9):937-43. doi: 10.1002/gps.2630. Epub 2010 Dec 28.

Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain

Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, Savva G, Brayne C, Wharton SB; MRC Cognitive Function and Ageing Neuropathology Study Group.

Neurobiol Aging. 2010 Apr;31(4):578-90. doi: 10.1016/j.neurobiolaging.2008.05.015. Epub 2008 Jun 30.

Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study

Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, Prinz B, Jahn H, Luckhaus Ch, Perneczky R, Hüll M, Schröder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kölsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J.

Mol Psychiatry. 2010 Feb;15(2):138-45. doi: 10.1038/mp.2008.84. Epub 2008 Jul 29.

Epigenetic changes in Alzheimer's disease: decrements in DNA methylation

Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J.

Neurobiol Aging. 2010 Dec;31(12):2025-37. doi: 10.1016/j.neurobiolaging.2008.12.005. Epub 2008 Dec 30.

Added diagnostic value of CSF biomarkers in differential dementia diagnosis

Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S.

Neurobiol Aging. 2010 Nov;31(11):1867-76. doi: 10.1016/j.neurobiolaging.2008.10.017. Epub 2009 Jan 15.

Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing

Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bürger K, Hampel H, Frölich L, Henn F, Falkai P, Rüther E, Jahn H, Luckhaus Ch, Perneczky R, Schmidtke K, Schröder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J.

Exp Neurol. 2010 Jun;223(2):366-70. doi: 10.1016/j.expneurol.2009.07.024. Epub 2009 Aug 5.

Amyloid beta and APP as biomarkers for Alzheimer's disease

Zetterberg H, Blennow K, Hanse E.

Exp Gerontol. 2010 Jan;45(1):23-9. doi: 10.1016/j.exger.2009.08.002. Epub 2009 Aug 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias